Jia et al. tested the CYP2C19 genotypes of 259 patients with acute cerebral infarction and evaluated the prognosis of stroke by mRS, and its results showed that the clinical outcomes of CYP2C19 LoFA carriers at 3 and 6 months after stroke were worse than non-carrying patients [20]. Here, CYP2C19 is linked to stroke disorder.